Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS.

Breast Cancer Res Treat. 2007 Dec;106(2):181-9. Epub 2007 Jan 27.

PMID:
17260090
2.

Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.

Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. Review.

3.
4.

New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.

Gennari A, Pronzato P.

Clin Breast Cancer. 2008 Dec;8 Suppl 4:S179-83. doi: 10.3816/CBC.2008.s.015. Review.

PMID:
19158039
5.

HER-2 and topoisomerase II as predictors of response to chemotherapy.

Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B.

J Clin Oncol. 2008 Feb 10;26(5):736-44. doi: 10.1200/JCO.2007.15.4716. Review.

PMID:
18258981
6.

Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?

Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M, Larsimont D.

Eur J Cancer. 2008 Dec;44(18):2791-8. doi: 10.1016/j.ejca.2008.09.014. Epub 2008 Nov 5. Review.

PMID:
18993056
7.

The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.

Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V.

Cancer Treat Rev. 2007 Feb;33(1):64-77. Epub 2006 Nov 17. Review.

PMID:
17113234
8.

The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.

Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A.

Cancer Treat Rev. 2009 Dec;35(8):662-7. doi: 10.1016/j.ctrv.2009.08.006. Epub 2009 Sep 15. Review.

PMID:
19758759
9.

Predictive factors for anthracycline-based chemotherapy for human breast cancer.

Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kono S, Morimoto K, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S.

Breast Cancer. 2010 Apr;17(2):103-9. doi: 10.1007/s12282-009-0152-6. Epub 2009 Aug 6. Review.

PMID:
19657712
10.

Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated.

Järvinen TA, Liu ET.

Cytopathology. 2003 Dec;14(6):309-13. Review.

PMID:
14632727
11.

Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

Romero A, Caldés T, Díaz-Rubio E, Martín M.

Clin Transl Oncol. 2012 Mar;14(3):163-8. doi: 10.1007/s12094-012-0779-1. Review.

PMID:
22374418
12.

Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge.

Munro AF, Cameron DA, Bartlett JM.

Oncogene. 2010 Sep 23;29(38):5231-40. doi: 10.1038/onc.2010.286. Epub 2010 Aug 2. Review.

PMID:
20676126
13.

[HER-2 and TOP 2A gene amplifications in urinary bladder carcinoma].

Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G.

Verh Dtsch Ges Pathol. 2002;86:176-83. Review. German.

PMID:
12647367
14.

Predicting anthracycline benefit: have we made any progress?

Moretti E, Oakman C, Di Leo A.

Curr Opin Oncol. 2009 Nov;21(6):507-15. doi: 10.1097/CCO.0b013e328331a501. Review.

PMID:
19713842
15.

[HER2 and topoisomerase II alpha: useful clinical markers in breast cancer].

Larsimont D, Durbecq V, Awada A, Di Leo A.

Bull Cancer. 2008 Mar;95(3):344-51. doi: 10.1684/bdc.2008.0596. Review. French.

16.
17.

Molecular assays in breast cancer pathology.

O'Toole SA, Selinger CI, Millar EK, Lum T, Beith JM.

Pathology. 2011 Feb;43(2):116-27. doi: 10.1097/PAT.0b013e3283430926. Review.

PMID:
21233672
18.

Adjuvant chemotherapy for the treatment of HER2-positive early breast cancer.

Clavarezza M, Venturini M.

Oncology. 2009;77 Suppl 1:14-7. doi: 10.1159/000258491. Epub 2010 Feb 2. Review.

PMID:
20130427
19.

Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T.

Am J Pathol. 2011 Apr;178(4):1453-60. doi: 10.1016/j.ajpath.2010.12.042. Review.

20.

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.

Jacot W, Fiche M, Zaman K, Wolfer A, Lamy PJ.

Biochim Biophys Acta. 2013 Aug;1836(1):146-57. doi: 10.1016/j.bbcan.2013.04.004. Epub 2013 Apr 26. Review.

PMID:
23628726

Supplemental Content

Support Center